Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Medical Informatics and Decision Making
Published in: BMC Medical Informatics and Decision Making 1/2017

Open Access 01-12-2017 | Research article

Information needs for making clinical recommendations about potential drug-drug interactions: a synthesis of literature review and interviews

Authors: Katrina M. Romagnoli, Scott D. Nelson, Lisa Hines, Philip Empey, Richard D. Boyce, Harry Hochheiser

Published in: BMC Medical Informatics and Decision Making | Issue 1/2017

Login to get access

Abstract

Background

Drug information compendia and drug-drug interaction information databases are critical resources for clinicians and pharmacists working to avoid adverse events due to exposure to potential drug-drug interactions (PDDIs). Our goal is to develop information models, annotated data, and search tools that will facilitate the interpretation of PDDI information. To better understand the information needs and work practices of specialists who search and synthesize PDDI evidence for drug information resources, we conducted an inquiry that combined a thematic analysis of published literature with unstructured interviews.

Methods

Starting from an initial set of relevant articles, we developed search terms and conducted a literature search. Two reviewers conducted a thematic analysis of included articles. Unstructured interviews with drug information experts were conducted and similarly coded. Information needs, work processes, and indicators of potential strengths and weaknesses of information systems were identified.

Results

Review of 92 papers and 10 interviews identified 56 categories of information needs related to the interpretation of PDDI information including drug and interaction information; study design; evidence including clinical details, quality and content of reports, and consequences; and potential recommendations. We also identified strengths/weaknesses of PDDI information systems.

Conclusions

We identified the kinds of information that might be most effective for summarizing PDDIs. The drug information experts we interviewed had differing goals, suggesting a need for detailed information models and flexible presentations. Several information needs not discussed in previous work were identified, including temporal overlaps in drug administration, biological plausibility of interactions, and assessment of the quality and content of reports. Richly structured depictions of PDDI information may help drug information experts more effectively interpret data and develop recommendations. Effective information models and system designs will be needed to maximize the utility of this information.
Appendix
Available only for authorised users
Literature
1.
Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti NP, Vilar S, Brochhausen M, Samwald M, Rastegar-Mojarad M, et al. Toward a complete dataset of drug-drug interaction information from publicly available sources. J Biomed Inform. 2015;55:206–17.CrossRefPubMedPubMedCentral
2.
Saverno KR, Hines LE, Warholak TL, Grizzle AJ, Babits L, Clark C, Taylor AM, Malone DC. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc. 2011;18:32–7.CrossRefPubMed
3.
Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, Abernethy DR, Horn JR, Sklar SJ, Wong SK, et al. Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf. 2015;38:197–206.CrossRefPubMedPubMedCentral
4.
Wang LM, Wong M, Lightwood JM, Cheng CM. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother. 2010;44:28–34.CrossRefPubMed
5.
Böttiger Y, Laine K, Andersson ML, Ovesjö M-l, Tirkkonen T, Rane A, Gustafsson LL, Eiermann B, Korhonen T, Molin B. SFINX-a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol. 2009;65:627–33.CrossRefPubMed
6.
Van Roon EN, Flikweert S, Le Comte M, Langendijk PNJ, Kwee-Zuiderwijk WJM, Smits P, Brouwers JRBJ. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf. 2005;28:1131–9.CrossRefPubMed
7.
Brochhausen M, Schneider J, Malone D, Empey PE, Hogan WR, Boyce RD. Towards a foundational representation of potential drug-drug interaction knowledge. In: The 1st International Drug-Drug Interaction Knowledge Representation Workshop (DIKR 2014) Collocated with the 2014 International Conference on Biomedical Ontology (ICBO 2014). Houston: CEUR-WS; 2014. p. 16–31. BT - CEUR Workshop Proceedings.
8.
Schneider J, Brochhausen M, Rosko S, Ciccarese P, Hogan WR, Malone D, Ning Y, Clark T, Boyce RD. Formalizing knowledge and evidence about potential drug-drug interactions. In: The International Workshop on Biomedical Data Mining, Modeling, and Semantic Integration: A Promising Approach to Solving Unmet Medical Needs (BDM2I 2015) at the 14th International Semantic Web Conference (ISWC): October 11, 2015 2015; Bethlehem, PA; 2015.
9.
Schneider J, Ciccarese P, Clark T, Boyce RD. Using the Micropublications ontology and the Open Annotation Data Model to represent evidence within a drug-drug interaction knowledge base. In: The 4th Workshop on Linked Science 2014— Making Sense Out of Data (LISC2014) Collocated with the 13th International Semantic Web Conference (ISWC2014). Trentino, Italy; 2014.
10.
11.
12.
13.
Hochheiser H, Ning Y, Hernandez A, Horn JR, Jacobson R, Boyce RD. Using Nonexperts for Annotating Pharmacokinetic Drug-Drug Interaction Mentions in Product Labeling: A Feasibility Study JMIR Res Protoc. 2016;5(2):e40. doi:10.​2196/​resprot.​5028. PMID: 27066806 PMCID: 4844909.
14.
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry drug interaction studies — study design, data analysis, implications for dosing, and labeling recommendations. 2012.
15.
16.
17.
Yeung CK, Yoshida K, Kusama M, Zhang H, Ragueneau-Majlessi I, Argon S, Li L, Chang P, Le CD, Zhao P, et al. Organ impairment—drug–drug interaction database: a tool for evaluating the impact of renal or hepatic impairment and pharmacologic inhibition on the systemic exposure of drugs. CPT: Pharmacometrics Syst Pharmacol. 2015;4(8):489–94.
18.
Corbin J, Strauss AL. Basics of qualitative research. 4th ed. Los Angeles: Sage Publications; 2014.
19.
Lazar J, Feng JH, Hochheiser H. Research methods in human-computer interaction. 2010.
20.
Friedman CP, Wyatt J. Evaluation methods in biomedical informatics. 2006.
21.
22.
23.
De Vries H, Elliott MN, Kanouse DE, Teleki SS. Using pooled kappa to summarize interrater agreement across many items. Field Methods. 2008;20:272–82.CrossRef
24.
Ekstein D, Tirosh M, Eyal Y, Eyal S. Drug interactions involving antiepileptic drugs: assessment of the consistency among three drug compendia and FDA-approved labels. Epilepsy Behav. 2015;44:218–24.CrossRefPubMed
25.
Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc. 2004;44:136–41.CrossRef
26.
Olvey EL, Clauschee S, Malone DC. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin Pharmacol Ther. 2010;87:48–51.CrossRefPubMed
27.
Boyce R, Gardner G, Harkema H. Using natural language processing to Extract Drug-Drug Interaction Information from Package Inserts. In: 2012 Workshop on BioNLP: 2012; Montreal. Quebec: Association for Computational Linguistics; 2012. p. 206–13.
28.
Bui Q-C, Sloot PMA, van Mulligen EM, Kors JA. A novel feature-based approach to extract drug-drug interactions from biomedical text. Bioinformatics (Oxford, England). 2014;30:3365–71.CrossRef
29.
Kim S, Liu H, Yeganova L, Wilbur WJ. Extracting drug-drug interactions from literature using a rich feature-based linear kernel approach. J Biomed Inform. 2015;55:23–30.CrossRefPubMedPubMedCentral
30.
Liu S, Tang B, Chen Q, Wang X. Drug-drug interaction extraction via convolutional neural networks. Comput Math Methods Med. 2016;2016:6918381.PubMedPubMedCentral
31.
Segura-Bedmar I, Martínez P, de Pablo-Sánchez C. Using a shallow linguistic kernel for drug-drug interaction extraction. J Biomed Inform. 2011;44:789–804.CrossRefPubMed
32.
Zhang Y, Lin H, Yang Z, Wang J, Li Y. A single kernel-based approach to extract drug-drug interactions from biomedical literature. PLoS One. 2012;7:e48901.CrossRefPubMedPubMedCentral
33.
Herrero-Zazo M, Segura-Bedmar I, Martínez P. Conceptual models of drug-drug interactions: a summary of recent efforts. Knowledge-Based Systems. 2016;114:99–107.CrossRef
34.
Beyer H, Holtzblatt K. Contextual design: defining customer-centered systems. 1998.
35.
Helmons PJ, Suijkerbuijk BO, Nannan Panday PV, Kosterink JGW. Drug-drug interaction checking assisted by clinical decision support: a return on investment analysis. J Am Med Inform Assoc. 2015;22:764–72.CrossRefPubMed
36.
Boyce RD, Horn JR, Hassanzadeh O, Waard A, Schneider J, Luciano JS, Rastegar-Mojarad M, Liakata M. Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness. J Biomed Semant. 2013;4(1):5.CrossRef
37.
Payne TH, Hines LE, Chan RC, Hartman S, Kapusnik-Uner J, Russ AL, Chaffee BW, Hartman C, Tamis V, Galbreth B, et al. Recommendations to improve the usability of drug-drug interaction clinical decision support alerts. J Am Med Inform Assoc. 2015;22:1243–50.CrossRefPubMed
38.
Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674–80.CrossRefPubMed
Metadata
Title
Information needs for making clinical recommendations about potential drug-drug interactions: a synthesis of literature review and interviews
Authors
Katrina M. Romagnoli
Scott D. Nelson
Lisa Hines
Philip Empey
Richard D. Boyce
Harry Hochheiser
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Medical Informatics and Decision Making / Issue 1/2017
Electronic ISSN: 1472-6947
DOI
https://doi.org/10.1186/s12911-017-0419-3

Other articles of this Issue 1/2017

BMC Medical Informatics and Decision Making 1/2017 Go to the issue

Research article

Development of a web-based patient decision aid for initiating disease modifying anti-rheumatic drugs using user-centred design methods

Research article

ACSC Indicator: testing reliability for hypertension

Research article

Reviewing clinical guideline development tools: features and characteristics

Research article

Use of electronic medical records and quality of patient data: different reaction patterns of doctors and nurses to the hospital organization

Research Article

Word2Vec inversion and traditional text classifiers for phenotyping lupus

Research article

Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial